Post hoc analysis of the phase III LIBERTY-CD trial (329 patients with Crohn's disease responding to IV infliximab): subcutaneous infliximab maintenance improved all week 54 endpoints vs placebo, with similar effects in ileum- and colon-dominant disease.
Secondary analysisn = 329 patients
Sands et al. Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study